We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

April 10, 2020

News You Need - 3 Big Little Things from HealthXL

Commentary
HealthXL Research Team
&

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar. Interested in getting beyond the headlines? We’ve included three industry experts who can help you get behind these stories - just let us know if you’d like us to make the introduction!


Mind Over Corona-Matter: The Growing Mental Health Crisis

Snapshot of the story

This week, the Office of New York Governor Andrew Cuomo announced a partnership with Headspace, a scientifically backed meditation, and mindfulness app, to provide all New Yorkers with access to free and specially curated mental health resources. 


Why it matters

Many are warning of an impending, secondary mental health crisis, fuelled by social distancing measures, social isolation and a sense of uncertainty coupled with the anxiety of contracting the virus. Research from the 2003 SARS outbreak found an association between PTSD, depression and the experience of being quarantined, the prevalence of which increased with longer quarantine durations.

Industry implications

While it’s fair to say that economic stabilization has taken precedence thus far, the New York City - Headspace partnership is a welcome first step towards psychological stabilization (though we need to see more concerted efforts).Digital health companies such as Thrivetalk are offering their mental health services free of charge to healthcare workers and are reducing their ordinary fees for everyone else. We’re seeing many companies foregoing profits in an unprecedented wave of solidarity.It’s uplifting to see big partnerships being formed with digital health companies other than those supporting the front-line combat against the virus. In fact, we’re also seeing a huge rise in demand for remote medicines, such as Livongo, whose stock rose by 10% a couple of days ago. This is especially welcoming news amid recent reports of furlough and layoffs in the digital health world.

Read more on this here

Pablo Pantaleoni
Pablo Pantaleoni
VP and General Manager of Health
Headspace Inc.

Pablo is the Vice President and General Manager of Health at Headspace. He leads the healthcare subsidiary that aims to develop digital therapeutic products to help mitigate and treat chronic health conditions. Pablo also co-leads the Digital Health NEXT Program at Stanford Biodesign.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

FDA and Covid-19 home testing: To approve or not to approve?

Snapshot of the Story

After just launching their at-home testing kits for Covid-19, numerous consumer diagnostic companies rescinded their offering this week following the FDA’s update to its Covid-19 Diagnostic Test Policy which specifies that Emergency Use Authorization (EUA) testing permissions do not extend to at-home testing kits.

Updated FDA COVID-19 testing guidelines specifically disallow at-home sample collection

Why it’s notable

The agency updated its policy shortly after it issued a public warning cautioning against "unauthorized fraudulent COVID-19 test kits" on the market. The agency further specified that “at this time, the FDA has not authorized any test that is available to purchase for testing yourself at home for COVID-19.”  

The earlier version of the testing policy had caused some confusion amongst consumer diagnostic companies (such as Carbon Health, Everlywell and Nurx) who raced to develop testing kits, thinking that compliance meant using CLIA certified laboratories to process samples. 

The policy restrictions present a particularly unfortunate setback at a time when testing is of paramount importance, but burdensome to health systems and at-home kits would have been the obvious solution.

 

Industry implications

  1. Not to criticise the FDA’s stance on home testing, but now is not a good time for regulatory ambiguity. 
  2. Despite the setback for home-testing, the EUA process is a sign of agile adaptation to an unprecedented situation. And the likes of Scanwell Health may be successful in bringing their blood-based test to the market via the EUA road.
  3. This is also not the first time we’ve seen a relaxation of rules amidst the Covid-19 pandemic. Just last week the privacy watchdog in the US announced that it would not enforce penalties for using non-HIPAA compliant telecommunication platforms during the pandemic.

 

For more information on Emergency Use Authorizations click HERE. The FDA’s FAQS on Diagnostic Testing can be found HERE. 

Peter Foley
Peter Foley
Founder & CEO
LetsGetChecked

Peter Foley leads consumer diagnostic efforts with Lets Get Checked. Connect with Peter to learn more about their response to COVID-19 and take on the testing developments in light of the pandemic.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Lessons learned from China?

Snapshot of the story 

A number of articles in recent weeks have tried to draw a parallel between China and Europe/ USA - what lessons we can learn from China to combat COVID-19 since they have somewhat successfully managed to 'flatten the curve'. The above is just one such example. However, I don't necessarily believe that a copy paste strategy is going to work for us.

How China is using robots and telemedicine to combat the coronavirus

Why it's notable

Quantifying the outbreak varies drastically across countries. R0 is a measure used in epidemiology to assess how contagious an infection is, or more specifically, how many people a person with the virus will infect. This is not a property of the virus but in fact a more variable concept that depends on demographics, socioeconomic, climatic factors,population density, etc. The R0 for China does not necessarily equal the R0 of other nations.  

I am no economist or civil engineer, but I can safely say the infrastructure in China - both physical, political and economic is not comparable to Europe/elsewhere, and therefore we cannot just replicate their moves like flying drones to 'watch' people who leave home, or set up very quick makeshift hospitals run by robots, set up mass body scanners, heat sensing cameras around the country, etc. 

 

Industry Implications 

While it is promising to see that one can 'flatten the curve' and limit the community transmission of cases, we are far from finished, since there's a good chance of resurgence if people go 'back to normal' before being vaccinated, and people from elsewhere start traveling to China. 

We are still in unknown territory with this disease, we have no herd immunity, the life sciences and tech industries need to come together. Some of the rapid telemedicine and chatbot adoption stories, rapid regulatory milestones being achieved, trials for treatments being accelerated into Phase III already make me wonder why it cannot always be like this!  

New game, new rules? Will all these changes help us adopt new (better?) ways of living permanently (now that we know what it's like sans carbon emissions, overconsumption) or will we just revert to old ways? 

Andrew Murphy
Andrew Murphy
Co-Founder, Executive Chairman Robotify
Robotify

Andrew Murphy is a key commercial advisor in the HealthXL community. Connect with Andrew to get his perspective of differing approaches globally and potential implications of those strategies.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.